Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. - Full Text View - ClinicalTrials.gov

Full Text View

This study is not yet open for participant recruitment.

Verified April 2013 by AstraZeneca

Sponsor:

AstraZeneca

Collaborator:

Gynecologic Oncology Group (GOG)

Information provided by (Responsible Party):

AstraZeneca

 

Purpose

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy